The primary hyperoxaluria market is set for substantial growth, driven by increased patient pool and expected drug launches. Lumasiran, a significant development, has been approved in the US and EU. However, the market is experiencing changes due to the closure of Allera Pharmaceuticals and the halt of reloxaliase trials by the company. Preclinical investigations are focused on orally administered formulations, while preclinical trials for therapies such as enzyme restoration therapy (ERT) and CRISPR-Cas9 SRT and ERT show promising results.

Hyperoxaluria Market Set for Growth